Freenome, Inc. FRNM
10.18 USD -0.29 (-2.77%)
At closeNov 6, 2026, 5:10 PM EST
10.21 +0.03 +0.29%
After hours · Nov 6, 5:10 PM ET
9.71 Day range 10.61
9.71 52-week range 17.50
- YTD
- -21.87%
- 1 year
- -5.13%
- Market cap
- 1.09B
- Revenue (ttm)
- 35.41M
- EPS (ttm)
- -2.04
- Shares out
- 107.45M
- Forward P/E
- -4.24
- YTD return
- -21.87%
- 1-year return
- -5.13%
- Volume
- 2.46M
- Avg volume
- 838.51K
- Open
- 10.61
- Previous close
- 10.47
- Day's range
- 9.71 – 10.61
- 52-week range
- 9.71 – 17.50
- Beta
- 0.60
- Price target
- 18.00 (+76.8%)
- Earnings date
- Nov 10, 2026
1m -0.43 (-4.05%)
Key statistics
- Enterprise value
- 2.70B
- PEG ratio
- 0.00
- Price / sales
- 30.89
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 106.50%
- Free cash flow
- 0
- Total cash
- 102.02M
- Total debt
- 311.45M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 14.52
- 200-day average
- 12.47
Analyst view
Price target (mean) 18.00 +76.8% upside
Now 10.18
- Target (low)
- 17.00
- Target (mean)
- 18.00
- Target (high)
- 21.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy0
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 10, 2026
Expected Nov 10, 2026. Consensus EPS estimate -0.195.
Financials — quick view
FRNM Revenue — quarterly 4.22M
FRNM Net income — quarterly -63.56M
FRNM EPS — quarterly -2.38
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 10, 2026 | Sep 30, 2026 | 0.1375 | — | — | — |
| Jul 15, 2026 | Jun 30, 2026 | -1.78 | -1.91 | -0.13 | -7.61% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 20, 2026 | Guggenheim | init | — | Buy |
| Aug 18, 2026 | TD Cowen | init | — | Buy |
| Aug 17, 2026 | Jefferies | init | — | Buy |
| Aug 17, 2026 | BTIG | init | — | Buy |
About Freenome, Inc.
Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- freenome.com
News
Freenome Unveils SimpleScreen Lung Enabling Patients To Be Screened For Lung And Colorectal Cancer Through Single Blood Draw, Using Two Independently Validated, Indication-Specific Tests 
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up 
Gap Posts Upbeat Q2 Earnings, Joins Solstice Advanced Materials, N-Able And Other Big Stocks Moving Higher On Friday 
Guggenheim Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $21 
Frenome Files Prospectus Related To The Offer And Sale From Time To Time By The Selling Securityholders Of Up To 75,188,742 Shares Of Common Stock 
TD Cowen Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $17 - Jefferies Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $17
BTIG Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $17 - Leerink Partners Initiates Coverage On Freenome with Outperform Rating, Announces Price Target of $18
Freenome Receives FDA Breakthrough Device Designation For Its Investigational Lung Cancer Screening Test SimpleScreen Lung
Your note
Sign in to keep a note on FRNM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALTMAN MICHAEL SETH | Former | Conversion of Exercise of derivative security | Jul 19, 2026 | 0 |
| EDELMAN JOSEPH E | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jul 19, 2026 | 0 |
| MCKENNA MARK C | Former | Conversion of Exercise of derivative security | Jul 19, 2026 | 30,000 |
| PERCEPTIVE CAPITAL SOLUTIONS HOLDINGS | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jul 19, 2026 | 0 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jul 19, 2026 | 0 |
| SONG KENNETH M.D. | Former | Conversion of Exercise of derivative security | Jul 19, 2026 | 30,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Citizens Financial Group Inc/RI | 0.64% | 684,946 | 6.97M | Sep 29, 2026 |
| Granite Investment Partners, LLC | 0.50% | 537,169 | 5.47M | Sep 29, 2026 |
| Wealth Enhancement Advisory Services, LLC | 0.27% | 290,453 | 2.96M | Sep 29, 2026 |
| Svrn Asset Management, LLC | 0.02% | 16,600 | 168.99K | Sep 29, 2026 |
| Bank Of New York Mellon Corporation | 0.01% | 13,303 | 135.42K | Sep 29, 2026 |
| FNY Investment Advisers, LLC | 0.00% | 3,500 | 35.63K | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK Venture Fund | 1.88% | 2,019,291 | 20.56M | Jul 30, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 0.69% | 742,035 | 7.55M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.37% | 397,340 | 4.04M | Sep 29, 2026 |
| T. ROWE PRICE Intl Fd.S, INC.-T. Rowe Price Global Stock Fd. | 0.22% | 238,855 | 2.43M | Jul 30, 2026 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 0.22% | 241,499 | 2.46M | Sep 29, 2026 |
| Federated Hermes World Investment Series, Inc.-Federated Hermes Intl S | 0.13% | 137,000 | 1.39M | Sep 29, 2026 |